Coronado Biosciences Reports on Separation of CB Pharma Acquisition Corp. Securities
07 January 2015 - 12:15AM
Coronado Biosciences, Inc. (Nasdaq:CNDO), founder of CB Pharma
Acquisition Corp., reports on the separation of CB Pharma
Acquisition Corp.'s (Nasdaq:CNLMU) securities into ordinary shares,
rights and redeemable warrants, from the units.
Holders of the units, according to EarlyBirdCapital, Inc., the
representative of CB Pharma Acquisition Corp.'s underwriters of the
initial public offering, will be able to separately trade the
ordinary shares, rights and redeemable warrants included in such
units commencing on or about January 7, 2015. The ordinary shares,
rights and redeemable warrants will be listed on the NASDAQ Capital
Market ("NASDAQ") under the symbols CNLM, CNLMR and CNLMW,
respectively. Units not separated will continue to be listed on
NASDAQ under the symbol CNLMU.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. The offering was made only by means of a prospectus,
copies of which may be obtained by visiting the U.S. Securities and
Exchange Commission website at http://www.sec.gov. Alternatively, a
copy of the prospectus relating to the offering may be obtained
from EarlyBirdCapital, Inc., 366 Madison Avenue, 8th Floor, New
York, NY 10017, Attn: Aimee Bloch, 212-661-0200.
About Coronado Biosciences
Coronado Biosciences is a biopharmaceutical company dedicated to
investing in, acquiring, developing and commercializing novel
pharmaceutical products. The Company's portfolio currently includes
novel immunotherapy agents for the treatment of autoimmune diseases
and cancer. As part of its growth strategy, the company plans to
leverage its biopharmaceutical business and drug development
expertise to acquire rights to, or to finance, innovative
pharmaceutical and biotechnology products, technologies and/or
companies, using a variety of approaches including licensing,
partnerships, joint ventures, direct financings and/or public and
private spin-outs. For more information, visit
www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other
statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks related to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; our
dependence on third party suppliers; our ability to attract,
integrate, and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
CONTACT: Lucy Lu, MD, Executive Vice President &
Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com
Origo Acquisition Corporation (NASDAQ:OACQU)
Historical Stock Chart
From May 2024 to Jun 2024
Origo Acquisition Corporation (NASDAQ:OACQU)
Historical Stock Chart
From Jun 2023 to Jun 2024